MDG: 34-10 Is Not Just a Hotel, but the Group’s Financing Lever
34-10 ended 2025 with 91.21% occupancy, $49.3 million of revenue, and $27.3 million of NOI. The combination of a $419 million value, $195 million of debt, and a loan extension through May 9, 2027 makes it an asset that creates financing room for the group, but also leaves the credit story leaning on one property.
The main article on MDG argued that the real test is not whether value exists in the assets, but whether that value turns into financing room and cash. 34-10 is where that translation has already happened in practice. It is one of the few assets in the portfolio where you can see strong occupancy, $27.291 million of NOI, a $419 million value, and a financing agreement that the lender not only extended, but repriced lower.
That is why this property matters more than the label "hospitality." It is not just another hotel in the portfolio, but the clearest financing lever in the group. On paper, against $195 million of specific debt, a $419 million value leaves a rough asset cushion of about $224 million before sale costs, taxes, and other frictions. That is not free cash, but it is exactly the cushion that helps negotiate, buy time, and release money from reserve accounts.
The other side of the same point is just as clear. If one asset is where the group buys time, air, and cheaper financing, then MDG’s credit story is still more concentrated in one Manhattan property than the property count suggests at first glance.
34-10 Already Behaves Like A Financing Asset
The 2025 numbers do not look like an asset still trying to find itself. The hotel ended the year with 91.21% average occupancy, $49.332 million of revenue, and $27.291 million of NOI, versus $43.413 million and $22.747 million in 2024. Book value also rose to $419 million from $381 million a year earlier.
What matters is not only that the hotel improved, but that its numbers are already large enough to change the financing language around it. In the company presentation, 34-10 is shown with a $419 million value, $195 million of debt, and only 46% loan to value. At the level of one single asset, that is a rare layer of relative stability inside a group whose entire local story runs through debt markets.
That point is reinforced by operating quality. The presentation shows average ADR of about $397 in 2025 versus about $365 in the prior comparable period, and the appraisal describes a 399-room Courtyard by Marriott property in a location that benefits from proximity to the Jacob Javits Center and Hudson Yards. This is not a "maybe one day" thesis. It is an asset that is already producing.
| Metric | End-2025 / March 2026 update | Why it matters |
|---|---|---|
| Asset value | $419 million | Explicit value in both the annual report and the appraisal |
| Specific debt | $195 million | The debt stack directly tied to the extension |
| Average occupancy | 91.21% | A level that helps explain why the lender stayed in |
| Revenue | $49.332 million | Large enough to matter to the group reading |
| NOI | $27.291 million | The operating cash layer supporting the financing package |
| Updated maturity | May 9, 2027 | The time the asset bought for the group |
The Appraisal Is More Conservative Than The Headline Value
Anyone looking only at the $419 million headline could assume that the whole 34-10 case rests on a big future upside. The appraisal says something more restrained. CBRE values the asset at $419 million as of December 31, 2025, and at $447.1 million on a stabilized basis as of December 31, 2027. The gap between those two states is only $28.1 million.
That is an important distinction because it changes how the asset should be read. 34-10 is not a financing lever because someone is underwriting a heroic future jump. It is a financing lever because the appraisal says most of the value already exists in the current state. In other words, the lender did not extend the loan in order to bet on a distant dream. It did so because the asset is already strong enough today.
Even the appraiser’s working assumptions are not especially aggressive. The DCF discount rate is 8.5%, and the stabilization date is set at December 31, 2027. More importantly, the NOI forecast does not assume a sharp ramp: after $27.170 million of NOI in 2026, the 2027 forecast is actually slightly lower at $26.473 million. That means the stabilized value rests more on time and the removal of the stabilization discount than on another large profit jump.
That sensitivity also shows up in the value matrix. At the same 6.25% terminal capitalization rate, moving the discount rate from 8.25% to 8.75% shifts DCF value from $426.7 million to $411.6 million.
That is still a meaningful cushion, but not one that justifies complacency. The appraiser also flags 744 new rooms in two nearby competing projects, so the asset remains strong, not untouchable.
March 2026 Turned Asset Quality Directly Into Financing
This is where 34-10 stops being a good hotel and becomes a financing lever for the group. On March 17, 2026, MDG exercised the second extension option on the loan through May 9, 2027. In the same move, the terms were amended so the spread fell to SOFR + 2.4% from SOFR + 3.25%, and the lender released $5.487 million from the dedicated expense account. On the other side, the company paid a $487.5 thousand extension fee.
The presentation adds the simple economic translation: estimated annual savings of about $1.7 million in financing expense. Relative to 2025 NOI, that is noticeable even if it does not, by itself, solve the group’s whole credit story.
| Item | Before the amendment | After the March 2026 amendment | Why it matters |
|---|---|---|---|
| Maturity date | May 9, 2026 | May 9, 2027 | Another year of balance-sheet time |
| Interest spread | SOFR + 3.25% | SOFR + 2.4% | Cheaper debt on one of the clearest financing assets in the portfolio |
| Dedicated account | Cash remained trapped | $5.487 million released | More flexibility at the asset-company level |
| One-time cost | None | $487.5 thousand | A relatively low price for the extra time and cheaper spread |
| Estimated annual saving | None | About $1.7 million | Better coverage and more financing air |
That is the core point. A revaluation can improve equity. A sale can generate a gain. But a loan extension that also lowers the spread and releases reserves is a real financing response to a real operating asset. That is why 34-10 is a financing lever, not just a value anchor.
It Is Still A Lever, Not A Full Solution
It is important not to overstate the other side either. An extension through May 9, 2027 is not a permanent solution, but a window of time. It says the hotel is strong enough to buy another year on better terms. It does not say the group’s financing story is fully solved.
The fact that the appraisal is relatively close between the as-is and stabilized cases sharpens that message. On one hand, it is a strength signal because the story does not depend on a huge "day after" jump. On the other hand, it means the margin of safety is not infinite. If the hotel’s performance weakens, there is no giant upside layer waiting to absorb any miss.
That is why 34-10 matters to the group in both directions. When it works, it gives the balance sheet time, lower interest cost, and released cash. If it stops working at that quality, the same asset quickly shifts from being the lever that eases pressure to being the concentration point that brings pressure back.
That is the right conclusion: 34-10 has already shown that it can do something for MDG that few other assets in the portfolio can do, turn operating performance into bargaining power with a lender. But for exactly that reason, even after 2025 and the March 2026 amendment, the group’s credit story still runs through one Manhattan hotel.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.